1. Extended-use adjuvant letrozole therapy was associated with significant reduction in breast cancer-free survival but not overall survival, compared to placebo.
2. Extended-use adjuvant letrozole therapy was associated with significantly more bone toxicity side effects compared to placebo.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Anti-estrogen therapies like tamoxifen, and aromatase...